Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis
Non-randomised trial
OA: closed
CC0
⤵ 10 in-corpus citations
AI-generated summary
Depot GnRH-agonist Zoladex treatment of 80 women with genital endometriosis resulted in objective improvement, symptom relief, and reduced hormone levels, with minimal side effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Eighty patients with different stages of genital endometriosis were treated with Zoladex, a gonadotrophin-releasing hormone analogue in a depot formulation, injected subcutaneously every 4 weeks. The stages of endometriosis (I-IV) were classified according to the revised American Fertility Society recommendations (AFS criteria) via pelviscopy before and after 6 months of treatment. Fifty-eight second-look pelviscopies were performed with the following objective changes after (before) treatment: Stage IV 0 (3); Stage III, 2 (13); Stage II, 12 (30); Stage I, 19 (12). Twenty-five patients presented with Stage 0 after therapy and were healed. All 57 symptomatic patients showed a subjective response to Zoladex therapy with a significant decrease of the total pelvic symptom score. Thirty-eight patients with infertility wished to become pregnant and so far 16 (40%) have conceived. During therapy, the serum concentrations of luteinizing hormone, follicle stimulating hormone, estradiol and progesterone were significantly suppressed. All patients were amenorrhoeic after 1-2 injections. Restoration of ovarian function with resumption of menstruation occurred within 57-92 days after the last injection of Zoladex (1-2 months after end of treatment). Side-effects were minimal and were those expected of the hypo-oestrogenic state, such as hot flushes, vaginal dryness and decrease of libido.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (10)
- Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment 2016
- Systematic review of endometriosis pain assessment: how to choose a scale? 2014
- The levonorgestrel-releasing intrauterine system and endometriosis staging 2007
- Diagnosis and treatment of endometriosis 2003
- Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis 2003
- Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis 2001
- Endometriosis: an overview of the disease and its treatment 2000
- Medical management of endometriosis and infertility 2000
- Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome 1997
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders 1996
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-05-11T06:01:13.017405+00:00
- pubmed
- last seen: 2026-10-08T21:05:10.907216+00:00
- unpaywall
- last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0
· commercial use OK